Rohto Pharmaceutical Unveils 2025-2035 Growth Strategy

Rohto Pharmaceutical Co ( (JP:4527) ) has issued an update.

Rohto Pharmaceutical Co., Ltd. has announced its Medium- to Long-Term Growth Strategy for 2025–2035, focusing on expanding its Self-care and Professional Care domains. The strategy includes global expansion, enhancing technological capabilities, and establishing a medical business foundation. Rohto aims to achieve net sales of 415 billion yen by 2030, with a focus on delivering new value in eye and skincare, advancing research in Phyto-Science, and developing new ophthalmic and regenerative medicine products. The company also plans to increase dividends sustainably while maintaining a strong financial structure.

The most recent analyst rating on (JP:4527) stock is a Buy with a Yen4770.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.

More about Rohto Pharmaceutical Co

Rohto Pharmaceutical Co., Ltd. is a company operating in the pharmaceutical industry, primarily focusing on over-the-counter (OTC) drugs. Their business scope includes the Self-care Domain, which encompasses quasi-drugs, cosmetics, health foods, and food products, as well as the Professional Domain, which includes prescription pharmaceuticals, medical devices, and cellular therapy products. The company aims to deliver health and well-being globally through its products and services.

Average Trading Volume: 1,357,607

Technical Sentiment Signal: Hold

Current Market Cap: Yen570.9B

For a thorough assessment of 4527 stock, go to TipRanks’ Stock Analysis page.